Airiver Medical Receives FDA IDE Approval for Pivotal Trial of Drug-Coated Balloon in Chronic Rhinosinusitis
核心洞察
Airiver Medical (搜索) secured FDA investigational device exemption (IDE) approval to begin a pivotal clinical trial of its ESSpand Sinus Drug Coated Balloon for chronic rhinosinusitis (搜索) patients.
The nationwide study will enroll up to 300 patients with chronic rhinosinusitis (搜索) with and without nasal polyps (搜索) to assess safety and efficacy as an adjunct to endoscopic sinus surgery.
The ESSpand DCB combines balloon dilation with paclitaxel drug coating to maintain symptom relief and prevent scarring and renarrowing of sinus drainage passageways.
Airiver Medical (搜索), a clinical-stage company focused on respiratory tract conditions, has received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate a pivotal clinical trial of its ESSpand Sinus Drug Coated Balloon (DCB) for patients with chronic rhinosinusitis (搜索) (CRS). The approval marks a significant regulatory milestone for the Brooklyn Park, Minnesota-based company as it advances toward potential commercialization of its innovative treatment approach.
Pivotal Trial Design and Patient Population
The nationwide study will enroll up to 300 patients suffering from CRS with and without nasal polyps (搜索). The trial is designed to assess the safety and efficacy of the ESSpand DCB as an adjunct to endoscopic sinus surgery (ESS). The study is intended to serve as the basis for Airiver Medical (搜索)'s regulatory submission to the FDA and eventual commercialization of the ESSpand DCB in the United States.
Technology and Mechanism of Action
The ESSpand DCB represents a novel approach that combines standard balloon dilation with targeted drug delivery. The device is designed to maintain symptom relief and prevent scarring and renarrowing of drainage passageways by applying a thin layer of a proprietary paclitaxel drug coating to the targeted tissue contemporaneously with balloon dilation of the restricted sinus drainage passageways.
"Securing IDE approval for this study means we are one step closer to being able to offer chronic rhinosinusitis (搜索) patients a treatment option that has the potential to finally give them the long-term relief they've been waiting for with fewer treatments," said Lixiao Wang, founder, chief executive officer and chief technology officer for Airiver Medical (搜索).
Addressing Unmet Medical Need
CRS is defined as long-term symptomatic inflammation of the nose and paranasal sinuses that persists for a minimum of three months despite intervention. According to the company, CRS is one of the most common chronic medical conditions in the world. For many CRS sufferers, medication alone is not enough, and they may choose to undergo surgery. Despite this initial surgery, symptoms often return and many patients undergo at least one additional surgery.
Regulatory Status and Development Pipeline
The Airiver DCB is currently an investigational device that has not received marketing authorization from the FDA and is not available for sale in the United States. Airiver Medical (搜索) is a clinical stage company developing technologies to help patients who suffer from certain respiratory tract conditions, with aims to improve the current standard of care for central airway stenosis (搜索) and chronic rhinosinusitis (搜索).
The company's Drug Coated Balloon technology could offer a new solution for these conditions, potentially creating sustained patency, better outcomes and fewer treatments for patients who currently face limited long-term treatment options.